rs113488022
|
|
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
BRAF (V600E) mutation was found in about one in two nodules with thyroid FNA read as SFM, its PPV to detect cancers was excellent, and its NPV was very poor.
|
31811566 |
2020 |
rs113488022
|
|
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
A BRAF V600E mutation was identified in 15% of PD-L1-positive malignancies.
|
31821747 |
2020 |
rs113488022
|
|
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
Reverse Phase Proteomic Array (RPPA, MD Anderson Cell Lines Project), RNAseq (Cancer Cell Line Encyclopedia) and vemurafenib sensitivity (Cancer Therapeutic Response Portal) data for BRAF-V600E cancer cell lines were curated.
|
31672130 |
2019 |
rs113488022
|
|
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
We performed a literature review of five commonly requested off-label IHC predictive biomarkers in gastrointestinal tract (GIT) malignancies: HER2, mismatch repair (MMR), PD-L1, BRAF V600E and ROS1.
|
31221175 |
2019 |
rs113488022
|
|
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
PGC1α-negative papillary cancer was associated with BRAF V600E mutation, large tumor size, extrathyroidal or lymphovascular invasion, lymph node metastasis, and advanced stage.
|
31333799 |
2019 |
rs113488022
|
|
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
In serrated adenomas, BRAF-V600E mutation does not seem to be associated with age and sex, with the prevalence of dysplasia and cancer and with the morphology of the dysplastic component.
|
30815911 |
2019 |
rs113488022
|
|
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
Our results highlight the need to evaluate the action of glucocorticoid on cancer progression in melanoma, thyroid and colon carcinoma in which B-RAF-V600E is a frequent oncogene, and cancers in which evasion from senescence has been shown.
|
31371485 |
2019 |
rs113488022
|
|
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
We previously repositioned the drug as the inhibitor of B-Raf V600E, but its anti-tumor effect in human cancer has never been reported.
|
30583070 |
2019 |
rs113488022
|
|
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
The BRAF (V600E) mutation is found in several human cancer, causing an increase of cell proliferation due to a modification of the ERK/MAPK-signal cascade.
|
31762942 |
2019 |
rs113488022
|
|
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
In the trial, the combination elicited partial responses in 33% of patients and led to stable disease in another 39% of patients with rare <i>BRAF</i> V600E-mutant malignancies.
|
31217294 |
2019 |
rs113488022
|
|
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
BRAF V600E Mutation in Multiple Primary Malignancies: A Hairy Affair.
|
30680261 |
2018 |
rs113488022
|
|
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
Regulation of mutant TERT by BRAF V600E/MAP kinase pathway through FOS/GABP in human cancer.
|
29422527 |
2018 |
rs113488022
|
|
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
BRAF V600E Gene Mutation Is Associated With Bilateral Malignancy of Papillary Thyroid Cancer.
|
30219154 |
2018 |
rs113488022
|
|
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
Methods In this phase II, open-label trial, patients with predefined BRAF V600E-mutated malignancies received dabrafenib 150 mg twice daily and trametinib 2 mg once daily until unacceptable toxicity, disease progression, or death.
|
29072975 |
2018 |
rs113488022
|
|
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
The expression profile of integrin receptors and osteopontin in thyroid malignancies varies depending on the tumor progression rate and presence of BRAF V600E mutation.
|
30449496 |
2018 |
rs113488022
|
|
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
With advances in RAF inhibitors and second-generation inhibitors including encorafenib and vemurafenib, which have been approved for treating BRAF-V600E malignancies, the combinatorial therapeutic strategies of RAF inhibitors elicit remarkable responses in patients with BRAF-V600E mCRC.
|
30122982 |
2018 |
rs113488022
|
|
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
As a single agent, vemurafenib is relatively ineffective in other V600E-positive malignancies</span>.
|
30036146 |
2018 |
rs113488022
|
|
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
Our findings provide evidence of critical survival signals in BRAF non-V600E mutant c</span>ancers, which could pave the way for effective treatment of these cancers.
|
29348459 |
2018 |
rs113488022
|
|
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
For the 37 cases cytologists favored to be cPTC, 31 (84%) had a molecular result that supported malignancy (28 BRAF V600E mutations, 2 NTRK1 fusions, 1 AGK-BRAF fusion).
|
29396809 |
2018 |
rs113488022
|
|
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
The presence of the noninheritable V600E BRAF mutation in this family supports Knudson's "double-hit" hypothesis for cancer development and suggests the involvement of more than 1 gene in the clinical expression of FNMTC.
|
29895015 |
2018 |
rs113488022
|
|
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
Patients with this cancer have a high frequency (~50%) of oncogenic <i>BRAF</i> mutations, particularly BRAF V600E.
|
29387237 |
2018 |
rs113488022
|
|
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
BRAF-V600E (1799T > A) is one of the most frequently reported driver mutations in multiple types of cancers, and patients with such mutations could benefit from selectively inactivating the mutant allele.
|
28918044 |
2017 |
rs113488022
|
|
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
In FNA biopsy samples (n=186), immunocytochemical expression of caveolin-1 and BRAF V600E mutation coincided with malignancy.
|
27818286 |
2017 |
rs113488022
|
|
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
Two of 5 patients with BRAF V600E had progression, including 1 GT-UMP with local recurrence and 1 malignant tumor with enlarging residual disease.
|
28834810 |
2017 |
rs113488022
|
|
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
Verteporfin is highly effective as concentrations of verteporfin that do not impact tumor formation restore BRAF inhibitor suppression of tumor formation, suggesting that co-treatment with agents that inhibit YAP1 and BRAF(V600E) may be a viable therapy for cancer stem cell-derived BRAF inhibitor-resistant melanoma.
|
29299145 |
2017 |